Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Catalent completed its $25 million expansion at a facility in Schorndorf, Germany, the company announced Monday. The facility hosts packing, storage and distribution services, with the expansion adding 32,000 square feet of storage space. The company broke ground at the site in April last year.
German pharma company Grünenthal is investing in its Latin American manufacturing facilities, according to a Wednesday release. It invested over €80 million ($87 million) to improve production in the continent. The company has 11 locations in the region.
Lucinda Crabtree will be the new CFO of Oxford Biomedica, replacing Stuart Paynter who is leaving the company in September, according to a Wednesday release. Crabtree was an exec at MorphoSys until its recent acquisition by Novartis.
Rentschler Biopharma has opened a new manufacturing line at a facility in Milford, MA. The expansion added four new 2,000-liter single-use bioreactors to make complex molecules. A customer project is already underway, with more lined up, the CDMO said July 11. This is the company’s largest expansion in over 150 years.
UK-based CDMO Upperton Pharma announced its first commercial manufacturing facility on Tuesday after it passed an MHRA inspection at a site in Nottingham, UK. It will make solid, liquid, semi-solid, nasal and inhaled pharmaceuticals at the facility.
Injectable CDMO Incog BioPharma is building a new 100,000-square-foot facility in Indiana. Construction will start in August. The facility will be designed for labeling, packaging and making autoinjectors and other pens, adding 100 new jobs, according to a Monday release.
Shine Technologies won a $32 million contract from the US Department of Energy to make the radioisotope molybdenum‑99. The new funding will help Shine’s ongoing efforts to build an isotope facility in Janesville, WI. SHINE plans to produce Mo-99 commercially in early 2027, the company said Wednesday.
Hikma was handed an FDA Form 483 after an inspection between May 29 and April 12 at its facility in Cherry Hill, NJ. The form detailed three observations: Quality control procedures were not followed, scientific methods to ensure product quality and strength were not done, and deficient smoke studies were recorded.
Fujifilm Diosynth Biotechnologies has partnered with the Technical University of Denmark to offer a training program at the manufacturer’s site in Hillerød, Denmark. This will help Fujifilm hire more than 750 people within a “concise time frame,” the company said Monday.
The CDMO arm of biotech Pluri is to manufacture two clinical-stage cell therapy assets for biotech company Kadimastem. One of the assets is being investigated in diabetes and the other in amyotrophic lateral sclerosis, the companies said Thursday.